Plain-English translation of NCT06383728 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called given before surgery in patients with a specific type of lung cancer (squamous cell carcinoma) that has an EGFR gene mutation. The study wants to see if taking this medication for at least 9 weeks before surgery is safe and helps shrink the cancer. This approach—giving targeted therapy before surgery rather than after—is relatively new for this type of cancer.
Squamous cell lung cancer with EGFR mutations is a rare subtype, and doctors don't yet have a clear best approach for treating it before surgery. This medication has worked well for other EGFR-mutated lung cancers, but researchers need to test whether giving it before surgery in this specific group is safe and beneficial.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take the medication by mouth at a dose of 80 mg once daily for at least 9 weeks. During this time, you will have regular check-ups with blood tests and imaging scans to monitor how the cancer is responding and check for side effects. After 9 weeks, you will have surgery to remove the cancer. The study team will then follow up with you to see how well you recover and how long the benefits last.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China